Release Date: January 28, 2026
Expiration Date: January 28, 2027
Activity Overview
Chronic myeloid leukemia (CML) remains a complex hematologic malignancy despite dramatic improvements in outcomes with tyrosine kinase inhibitors (TKIs). As 6 TKIs are now FDA approved for CML, each with unique efficacy and safety profiles, clinicians face challenges in sequencing these agents, managing resistance, and addressing treatment-related adverse events. Continuous education is needed to help clinicians integrate new evidence, optimize therapeutic decisions, and enhance multidisciplinary collaboration to improve patient outcomes.
This Medical Crossfire® symposium features concise didactic updates and an expert panel debate. Through real-world case discussions, polling, and Q&A, participants will explore the evolving role of TKIs, resistance mechanisms, and emerging therapies.
This educational activity is an archive of the live presentation held on December 15, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward hematologists/oncologists, nurses, nurse practitioners, physician assistants, pharmacists, and any other health care providers involved in the diagnosis and treatment of CML.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze the latest clinical data on first-line therapies and apply emerging evidence to optimize initial treatment selection in CML
- Evaluate strategies for treatment sequencing across multiple lines of therapy in CML
- Implement effective approaches to manage adverse events and enhance patient safety
- Develop individualized care plans that improve outcomes and support long-term disease management
Jorge E. Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr, GRA Eminent Scholar Chair in Cancer
Georgia Research Alliance
Augusta University
Augusta, GA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Ascentage, Janssen, Novartis, Sun Pharma, Tern Pharma; Grant/Research Funding (to institution): Ascentage, CytoAgents, Kuro Oncology, Novartis, Tern Pharma
Hagop Kantarjian, MD
Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Consultant: AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Pfizer, Takeda; Grant/Research Support: AbbVie, Amgen, Ascentage, Pfizer, Takeda
Neil P. Shah, MD, PhD
Edward S. Ageno Distinguished Professor in Hematology/Oncology
Director, UCSF Molecular Medicine Residency Program
Chair, NCCN CML Guidelines Panel
University of California, San Francisco
San Francisco, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Novartis; Grant/Research Support: Kumquat Biosciences
Kendra Sweet, MD
Associate Member, Department of Malignant Hematology
H. Lee Moffitt Cancer Center and Research Institute
Assistant Professor, Department of Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Ascentage, Crossbow, Menarini Stemline, Xspray; Ownership interests in publicly traded companies: BeOne Pharmaceuticals
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
